Acesso livre
Acesso livre

Infectologia

OMS, CDC | Progresso global contra o sarampo fica ameaçado em meio à pandemia de COVID-19.

12 Nov, 2021 | 13:36h

Comunicado de imprensa: Global progress against measles threatened amidst COVID-19 pandemic – World Health Organization

Relatório: Progress Toward Regional Measles Elimination — Worldwide, 2000–2020 – CDC Morbidity and Mortality Weekly Report

Comentário: Measles is a renewed global threat after 22 million babies missed their vaccines during the pandemic, CDC warns – CNN

 

Comentário no Twitter (fio – clique para saber mais)

 

Estimativa dos danos diários causados pelos antibióticos: uma revisão ampla com metanálise – “Cada dia de antibioticoterapia foi associado com aumento de 4% nas chances de ocorrer um evento adverso.”

12 Nov, 2021 | 13:56h

Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis – Clinical Microbiology and Infection

 

Comentário no Twitter

 

Diretrizes IDSA sobre prevenção de infecção para profissionais de saúde que cuidam de pacientes com COVID-19 suspeitada ou conhecida.

11 Nov, 2021 | 16:25h

Infectious Diseases Society of America Guidelines on Infection Prevention for Healthcare Personnel Caring for Patients with Suspected or Known COVID-19

 

Comentário no Twitter

 

Pílulas antivirais contra COVID: o que os cientistas ainda precisam saber – “Medicações como molnupiravir e paxlovid podem mudar o curso da pandemia se os resultados de ensaios clínicos se repetirem no mundo real.”

11 Nov, 2021 | 16:23h

COVID antiviral pills: what scientists still want to know – Nature

Conteúdos relacionados:

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Podcast | Atualizações sobre COVID: edição do paciente ambulatorial.

11 Nov, 2021 | 16:21h

COVID Updates: The Outpatient Edition – The Curbsiders

 

Comentário no Twitter

 

Perspectiva | Como será o fim da pandemia: cientistas têm pistas sobre a evolução do SARS-CoV-2.

11 Nov, 2021 | 16:20h

COVID’s endgame: Scientists have a clue about where SARS-CoV-2 is headed – NPR

M-A | Baixos níveis de vitamina D não agravam o risco de infecção ou morte por COVID-19, e a suplementação de vitamina D não melhora os desfechos em pacientes internados com COVID-19.

11 Nov, 2021 | 16:18h

Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs – Nutritional Journal

Atualização sobre a síndrome inflamatória multissistêmica em crianças relacionada ao SARS-CoV-2.

11 Nov, 2021 | 16:17h

An Update on Multisystem Inflammatory Syndrome in Children Related to SARS-CoV-2 – The Pediatric Infectious Diseases Journal

Conteúdos relacionados:

Ten Things to Know About Multisystem Inflammatory Syndrome in Children (MIS-C).

Cohort study: long term follow-up showed most patients with post–COVID-19 Multisystem Inflammatory Syndrome in Children had good outcomes with no significant medium- or long-term sequelae.

Kawasaki Disease and Multisystem Inflammatory Syndrome in Children: An Overview and Comparison.

Cohort study: Six month follow-up of Multisystem Inflammatory Syndrome in Children.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, there was no evidence that recovery differed after primary treatment with intravenous immune globulin (IVIG) alone, IVIG plus glucocorticoids, or glucocorticoids alone.

Cohort study: Among children with Multisystem Inflammatory Syndrome (MIS-C) associated with Covid-19, initial treatment with intravenous immune globulin (IVIG) plus glucocorticoids was associated with a lower risk of new or persistent cardiovascular dysfunction than IVIG alone.

Cohort study showed that the incidence of Multisystem Inflammatory Syndrome in Children (MIS-C) was 316 persons per 1 000 000 SARS-CoV-2 infections in persons younger than 21 years. The incidence was higher among Black, Hispanic or Latino, and Asian or Pacific Islander persons.

Cohort study showed good recovery for most children 6 months after Pediatric Inflammatory Multisystem Syndrome (PIMS-TS) associated with SARS-CoV-2.

Epidemiology of Multisystem Inflammatory Syndrome in Children: A Step Closer to Understanding Who, Where, and When

Neurologic involvement in children and adolescents with COVID-19 or Multisystem Inflammatory Syndrome

Clinical Update: Acute covid-19 and multisystem inflammatory syndrome in children

Differences in characteristics and outcomes of children and adolescents with Multisystem Inflammatory Syndrome in Children (MIS-C) vs. severe acute COVID-19

Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)

SR: Multisystem inflammatory syndrome in children related to COVID-19

Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children

ACR Guidance for pediatric patients with multisystem inflammatory syndrome in children associated with SARS‐CoV‐2

New systematic review of Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 infection summarizes the clinical features, management, and outcomes of the disease, showing favorable outcomes for the majority of children

Estudo randomizado | Vacina da Pfizer mostra 90,7% de eficácia na prevenção de Covid-19 em crianças de 5 a 11 anos de idade.

10 Nov, 2021 | 12:55h

Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age – New England Journal of Medicine

 

Comentário no Twitter

 

Como um surto se tornou uma pandemia: análise cronológica de conjunturas cruciais e obrigações internacionais nos meses iniciais da pandemia de COVID-19.

10 Nov, 2021 | 12:53h

How an outbreak became a pandemic: a chronological analysis of crucial junctures and international obligations in the early months of the COVID-19 pandemic – The Lancet

 

Comentário no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.